Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient

Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient

Psoriasis is a chronic inflammatory skin disease associated with multisystem comorbidities and impaired mental health. The lesions are typically characterized by sharply demarcated, erythematous plaques covered with silvery scales. Treatment options include topical agents, phototherapy, systemic the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jianhao Ke, Meiliang Guo, Xuan Zhao, Na Liu, Qinqin Meng, Hui Deng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	immune checkpoint therapy cutaneous adverse effects psoriasis biologics cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573495/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Successful Psoriasis Management With Deucravacitinib After Guselkumab‐Associated Eosinophilic Pneumonia
by: Katie K. Lovell, et al.
Published: (2025-06-01)

Successful Guselkumab Treatment in a Patient with Comorbid Psoriasis and Amyotrophic Lateral Sclerosis: A Case Study and Literature Review
by: Xiong J, et al.
Published: (2025-03-01)

Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report
by: Qian Hao, et al.
Published: (2025-07-01)

Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis
by: Zhihui Yang, et al.
Published: (2025-03-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
by: Natalie Bourand, MS, et al.
Published: (2025-02-01)

Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report
by: Chenxi Zhang, et al.
Published: (2025-04-01)

Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer
by: Peipei Mou, et al.
Published: (2025-04-01)

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
by: Maryia Zhdanava, et al.
Published: (2024-12-01)

Pathogenesis, diagnosis and treatment of immune checkpoint inhibitor related bullous pemphigoid
by: Yi SUN, et al.
Published: (2025-04-01)

Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2025-07-01)

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
by: Emma L. Myers, BA, et al.
Published: (2025-04-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge
by: Ying-Jie Su, et al.
Published: (2025-08-01)

Novel Approach for Evaluating the Effectiveness of Biological Drugs in Patients with Plaque Psoriasis: Real-World Experience of a Single-Centre Study in Poland
by: Kimak-Pielas A, et al.
Published: (2025-06-01)

Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience
by: Bertoli C, et al.
Published: (2025-06-01)

Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis
by: Nikki Zangenah, BA, et al.
Published: (2025-06-01)

Role of methotrexate in biologics use with psoriasis and psoriatic arthritis
by: Ting-Ting Cheng, et al.
Published: (2025-04-01)

Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
by: E. A. Degtiareva, et al.
Published: (2022-11-01)

Demographics, Clinical Characteristics, and Treatment Patterns in Patients with Psoriasis: Insights from the Saudi Arabia Psoriasis Registry (PSORSA)
by: Mohammad Ibrahim Fatani, et al.
Published: (2025-05-01)

Influence of Melatonin on the state of immunity at psoriasis
by: V. S. Dmitruk, et al.
Published: (2009-08-01)

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0
by: Rodrigo Ramella Munhoz, et al.
Published: (2022-10-01)

Immune checkpoint Inhibitor related myocarditis reported through the FDA adverse event reporting system: pharmacovigilance trends in reporting and outcomes
by: David J. Reeves, et al.
Published: (2025-02-01)

Complete treatment experience on psoriasis patients with secukinumab in real practice in Krasnodar region
by: L. S. Kruglova, et al.
Published: (2021-06-01)

Gender differences in the association between adverse childhood experiences and early onset psoriasis
by: Sarnai Arlud, et al.
Published: (2025-08-01)

Psoriasis exacerbation following intravesical BCG immunotherapy for bladder carcinoma: A case report
by: Yusuf Can Edek, et al.
Published: (2025-07-01)

Ustekinumab Efficacy in Children with Palmoplantar Psoriasis: Case Series
by: Maria A. Leonova, et al.
Published: (2024-11-01)

The Systemic Immune‐Inflammation Index and Its Association With Biologic Therapy Switching and Response in Psoriasis
by: Gregg Murray, et al.
Published: (2025-06-01)

Application of Immune Checkpoint Inhibitors in Cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies
by: Jixuan Zheng, et al.
Published: (2025-04-01)

Successful treatment with sintilimab for SMARCA4-deficient non-small cell lung carcinoma: two case reports
by: Liwen Wang, et al.
Published: (2025-07-01)

Unique skin nodules following COVID-19 vaccination: a case report of cutaneous plasmacytosis and review of the literature
by: Xiaoxi Xu, et al.
Published: (2025-03-01)

Identification of STAT3 and BIRC5 as anoikis-related biomarkers in psoriasis
by: Wanting Bai, et al.
Published: (2025-08-01)

Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
by: Malak Al-Gawahiri, et al.
Published: (2025-12-01)

Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
by: Xu Y, et al.
Published: (2025-05-01)

Generalized pustular psoriasis with breast cancer successfully treated with granulocyte and monocyte adsorptive aphaeresis and brodalumab
by: Miho Takahashi, et al.
Published: (2025-03-01)

Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
by: Liz S. Gea, et al.
Published: (2024-10-01)

Overlap of myasthenia gravis, myocarditis, and inflammatory myopathy secondary to immune checkpoint inhibitor (pembrolizumab) on a background of previously undiagnosed thymoma-associated acetylcholine receptor antibody-positive myasthenia gravis
by: O. V. Finleyson
Published: (2025-04-01)

Multiple Biologics Treatment Failures in Patients with Psoriasis: A Case Series of 4 Patients
by: Mikkel Bak Jensen, et al.
Published: (2025-03-01)

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis
by: Linda T.H. Godding, et al.
Published: (2025-06-01)

Immunogenicity induced by biologicals in the treatment of psoriasis and psoriatic arthritis: View of the problem
by: T. V. Korotaeva
Published: (2016-01-01)